Supernus Pharmaceuticals reported a strong first quarter in 2021, with total revenues reaching $130.9 million, a 38% increase compared to the same period in 2020. Net product sales were $128.4 million, a 39% increase year-over-year. The company's operating earnings were $13.2 million, and net earnings were $5.7 million, or $0.11 per diluted share.
Total revenues for Q1 2021 reached $130.9 million, a 38% increase compared to 2020.
Net product sales for Q1 2021 were $128.4 million, 39% higher than the same period in 2020.
Qelbree was approved by the FDA for pediatric ADHD and is on track for a U.S. launch in Q2 2021.
Operating earnings for Q1 2021 were $13.2 million, compared to $29.0 million in Q1 2020.
For full year 2021, the Company reiterates its prior financial guidance and added full year 2021 effective tax rate guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance